Skip to main content

Table 1 Outcomes data by visit (the number of evaluable data per visit are used for calculations)

From: Sativex® (nabiximols) cannabinoid oromucosal spray in patients with resistant multiple sclerosis spasticity: the Belgian experience

  

Test treatment

Continued treatment

 

Baseline

Visit 1

(± 4 weeks)

Visit 2

(± 8 weeks)

Optional visit

(± 12 weeks)

6 months

12 months

N

238

238

230a

b

180

113

NRS

eN

238

229

188

96

103

60

 Mean

8.1 ± 1.08

5.2 ± 1.85

4.6 ± 1.69

4.1 ± 1.78

4.3 ± 1.77

4.0 ± 1.92

 Median

7.55 (2–10)

5 (0–10)

5 (0–9)

4 (0–9)

5 (0–9)

4 (0–9)

VAS

eN

231

217

186

93

101

54

 Mean

39 ± 22

52 ± 19

57 ± 20

59 ± 20

61 ± 18

64 ± 18

 Median

40 (0–95)

50 (5–95)

60 (10–96)

65 (10–93)

65 (20–90)

70 (30–99)

Number of sprays/day

eN

 

124

147

85

86

50

 Mean

 

5.6 ± 2.31

5.9 ± 2.53

5.9 ± 2.39

6.0 ± 2.25

5.7 ± 2.08

 Median

 

6 (1–12)

6 (1–12)

6 (1–12)

6 (1–12)

6 (1–12)

  1. aAccording to Belgian reimbursement criteria (period 01 January 2016–28 February 2020) patients were assessed for response after a minimal 8 weeks of treatment
  2. b12-week assessment was mandatory only for patients with > 20 and < 30% NRS improvement from week 4 to week 8, thus not possible to predict N